The Online Investor
Provention Bio Inc (PRVB)

Provention Bio is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Co.'s pipeline includes: PRV-031, an anti-CD3 monoclonal antibody for the interception of type 1 diabetes; PRV-101, a coxsackie virus B vaccine to prevent acute infections; PRV-3279, a humanized bispecific scaffold molecule targeting the B-cell surface proteins, for the treatment of systemic lupus erythematosus; PRV-015, a human anti-interleukin 15 monoclonal antibody for the treatment of gluten-free diet non-responding celiac disease; and PRV-6527, an oral small molecule CSF-1R inhibitor.

PRVB SEC Filing Email Alerts Service
Company Name: 
Provention Bio Inc
Drugs & Pharmaceuticals
Number of ETFs Holding PRVB: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (3.83 out of 4)
75th percentile
(ranked higher than approx. 75% of all stocks covered)

Analysts' Target Price:
PRVB Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Provention Bio Inc (PRVB) Page | The Online Investor Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.